Institutional shares held 71.8 Million
283K calls
233K puts
Total value of holdings $1.59B
$6.28M calls
$5.15M puts
Market Cap $1.58B
70,354,600 Shares Out.
Institutional ownership 102.08%
# of Institutions 231


Latest Institutional Activity in BEAM

Top Purchases

Q3 2024
International Assets Investment Management, LLC Shares Held: 64.3K ($1.45M)
Q3 2024
Handelsbanken Fonder Ab Shares Held: 28.5K ($641K)
Q3 2024
Cambridge Investment Research Advisors, Inc. Shares Held: 10.4K ($235K)
Q3 2024
China Universal Asset Management Co., Ltd. Shares Held: 16.1K ($362K)
Q3 2024
Arcadia Investment Management Corp Shares Held: 4K ($90K)

Top Sells

Q3 2024
Krilogy Financial LLC Shares Held: 10.9K ($246K)
Q3 2024
Sg Americas Securities, LLC Shares Held: 10.1K ($228K)
Q3 2024
New York State Common Retirement Fund Shares Held: 22.7K ($511K)
Q3 2024
Us Bancorp \De\ Shares Held: 584 ($13.1K)
Q3 2024
Steel Peak Wealth Management LLC Shares Held: 17.4K ($390K)

About BEAM

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


Insider Transactions at BEAM

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
262K Shares
From 8 Insiders
Grant, award, or other acquisition 210K shares
Exercise of conversion of derivative security 51.8K shares
Sell / Disposition
1.29M Shares
From 8 Insiders
Open market or private sale 1.27M shares
Other acquisition or disposition 29.5K shares

Track Institutional and Insider Activities on BEAM

Follow Beam Therapeutics Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BEAM shares.

Notify only if

Insider Trading

Get notified when an Beam Therapeutics Inc. insider buys or sells BEAM shares.

Notify only if

News

Receive news related to Beam Therapeutics Inc.

Track Activities on BEAM